Skip to main content

Body Roundness Index Trajectory Tied to Risk for Cardiovascular Disease

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 30, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Sept. 30, 2024 -- A higher body roundness index (BRI) trajectory is associated with an increased risk for cardiovascular disease (CVD), according to a study published online Sept. 25 in the Journal of the American Heart Association.

Man Yang, M.D., from The Affiliated Wuxi Center for Disease Control and Prevention of Nanjing Medical University in China, and colleagues examined the association of BRI trajectories with CVD among 9,935 middle-aged and older Chinese people in a longitudinal cohort. Group-based trajectory modeling was used to identify BRI trajectories.

Participants were classified into low-stable, moderate-stable, and high-stable BRI trajectories, accounting for 49.81, 42.35, and 7.84 percent of the study population, respectively. The researchers found that participants in the moderate-stable and high-stable BRI trajectory groups had an increased risk for CVD compared with participants in the low-stable trajectory group, with multivariable adjusted hazard ratios of 1.22 and 1.55, respectively. CVD risk reclassification was improved by simultaneously adding the BRI trajectory to the conventional risk model.

"The longitudinal trajectory of the BRI could be used as a novel indicator of CVD risk, providing a new possibility for CVD prevention," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted September 2024

Read this next

Few Adolescents With Obesity Prescribed Obesity Medications

FRIDAY, June 13, 2025 -- Despite an increase in the prevalence of prescribing, only 0.5 percent of U.S. adolescents with obesity were prescribed an obesity medication in 2023...

Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials

THURSDAY, June 12, 2025 -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower...

Adherence to Healthy Diet Improves Cardiometabolic Risk, Even Without Weight Loss

WEDNESDAY, June 11, 2025 -- A healthy diet improves cardiometabolic risk factors, even if not associated with weight loss (WL), according to a study published online June 5...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.